Fibrate Seems to Reduce CVD Risk in Diabetic Women
(MedPage Today) -- Contrary to earlier results, fenofibrate may actually lower cardiovascular risk in women with type 2 diabetes, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 19, 2014 Category: Cardiology Source Type: news
Fenofibrate also effective for women with type 2 diabetes
Blood-fat lowering drug fenofibrate is beneficial for women with type 2 diabetes, according to new research. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - August 19, 2014 Category: Nursing Source Type: news
Fenofibrate Works as Well in Women With Diabetes as in MenFenofibrate Works as Well in Women With Diabetes as in Men
Fenofibrate appears to work as well in women with type 2 diabetes as in men, according to a new FIELD analysis, providing reassurance after the ACCORD Lipid trial. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 18, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Fenofibrate and Renal DiseaseFenofibrate and Renal Disease
Find out more about the potentially cardioprotective effects of fenofibrate for patients with type 2 diabetes. Clinical Lipidology (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - January 11, 2014 Category: Urology & Nephrology Tags: Cardiology Journal Article Source Type: news
HDL-C Lowering Seen in Some Patients on Fibrate/TZD ComboHDL-C Lowering Seen in Some Patients on Fibrate/TZD Combo
Data from the ACCORD trial suggest that in a small number of patients, perhaps with a particular genetic background, the combination of fenofibrate and a TZD dramatically lowers HDL cholesterol. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Odd HDL Finding Seen in Diabetes Trial (CME/CE)
(MedPage Today) -- Among patients with type 2 diabetes, treatment with both fenofibrate and a thiazolidinedione was paradoxically tied to a higher likelihood of having an extremely low HDL cholesterol level, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 4, 2013 Category: Cardiology Source Type: news
World First Approval for Fenofibrate in Diabetic RetinopathyWorld First Approval for Fenofibrate in Diabetic Retinopathy
The established cholesterol-lowering drug fenofibrate has received first approval globally to slow the progression of diabetic retinopathy in patients with type 2 diabetes in Australia. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Fish Oil vs. Drugs for Hypertriglyceridemia in HIV+ PatientsFish Oil vs. Drugs for Hypertriglyceridemia in HIV+ Patients
Is fish oil as effective as fenofibrate, gemfibrozil, and atorvastatin in reducing triglyceride levels in HIV patients? JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 8, 2013 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news
Antara (Fenofibrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 4, 2013 Category: Drugs & Pharmacology Source Type: news
EMA Panel Gives Thumbs-up to Fenofibrate/Simvastatin ComboEMA Panel Gives Thumbs-up to Fenofibrate/Simvastatin Combo
The drug, known as Cholib, received a "positive opinion" from CHMP for two doses of the fenofibrate/simvastatin combination. A positive opinion is a prerequisite to approval by the European Commission, which has 67 days from the date of the opinion to grant approval. International Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 28, 2013 Category: Cardiology Tags: Cardiology News Alert Source Type: news
EMA advisory committee gives thumbs-up to fenofibrate/simvastatin combo
The drug, known as Cholib, received a "positive opinion" from CHMP for two doses of the fenofibrate/simvastatin combination. A positive opinion is a prerequisite to approval by the European Commission, which has 67 days from the date of the opinion to grant approval. (Source: theHeart.org)
Source: theHeart.org - June 28, 2013 Category: Cardiology Source Type: news
Mylan Launches Generic Antara® Capsules
Mylan Inc. (Nasdaq:MYL) today announced that its subsidiary Mylan Pharmaceuticals has begun shipping Fenofibrate Capsules USP, 43 mg and 130 mg. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 26, 2013 Category: Pharmaceuticals Source Type: news
